Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05936996 · ClinicalTrials.gov registry record
Prospective Clinical Registry Evaluating Contemporary MANTA Outcomes
A clinical trial, sponsored by Essential Medical.
- Completed
- Registry status
- 258
- Enrollment target
NCT05936996: Completed study, sponsored by Essential Medical.
NCT05936996 is a clinical trial that has completed, run by Essential Medical. The registered enrollment target is 258 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05936996 has completed, sponsored by Essential Medical.
- COMPLETED
- Registry status
- 258 participants
- Enrollment target
Study Summary
This is an observational study designed to evaluate the safety and clinical outcomes of the MANTA® Vascular Closure Device (VCD) (the MANTA® Device) in TAVR procedures. The study will enroll participants who are undergoing a TAVR procedure. The purpose of this study is to examine and collect data on outcomes of contemporary MANTA® large bore closure in standard of care (SOC) TAVR procedures with on-label use of the MANTA® device including appropriate patient selection and proper vascular access.
Interventions
- DEVICE MANTA Vascular Closure Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2023-11-15 |
| Est. Completion | 2025-10-30 |
What the finished NCT05936996 record still lists
NCT05936996 is an observational study that tracks outcomes without assigning an intervention. The registered 258 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which MANTA Vascular Closure Device is the first listed.
NCT05936996 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05936996 about?
NCT05936996 is a clinical study titled "Prospective Clinical Registry Evaluating Contemporary MANTA Outcomes". This is an observational study designed to evaluate the safety and clinical outcomes of the MANTA® Vascular Closure Device (VCD) (the MANTA® Device) in TAVR procedures. The study will enroll participants who are undergoing a TAVR procedure. The purpose of this study is to examine and collect data on...
What is the current status of trial NCT05936996?
This trial is currently completed. The enrollment target is 258 participants. The study started on 2023-11-15. Estimated completion is 2025-10-30.
What interventions are being tested in trial NCT05936996?
The interventions under investigation include: MANTA Vascular Closure Device (DEVICE).
Who is sponsoring clinical trial NCT05936996?
This trial is sponsored by Essential Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03785288 · 258 participants · Phase 3
Vaginal Cuff Brachytherapy Fractionation Study
- NCT04643002 · 258 participants · Phase 1
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- NCT04924322 · 258 participants · Phase 2
Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies
- NCT05043012 · 258 participants · NA
Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI